Literature DB >> 8874839

Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients.

A L Stoll1, G S Sachs, B M Cohen, B Lafer, J D Christensen, P F Renshaw.   

Abstract

This study examined choline augmentation of lithium for rapid-cycling bipolar disorder. Choline bitartrate was given openly to 6 consecutive lithium-treated outpatients with rapid-cycling bipolar disorder. Five patients also underwent brain proton magnetic resonance spectroscopy. Five of 6 rapid-cycling patients had a substantial reduction in manic symptoms, and 4 patients had a marked reduction in all mood symptoms during choline therapy. The patients who responded to choline all exhibited a substantial rise in the basal ganglia concentration of choline-containing compounds. Choline was well tolerated in all cases. Choline, in the presence of lithium, was a safe and effective treatment for 4 of 6 rapid-cycling patients in our series. A hypothesis is suggested to explain both lithium refractoriness in patients with bipolar disorder and the action of choline in mania, which involves the interaction between phosphatidylinositol and phosphatidylcholine second-messenger systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874839     DOI: 10.1016/0006-3223(95)00423-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

1.  Lithium does not alter the choline/creatine ratio in the temporal lobe of human volunteers as measured by proton magnetic resonance spectroscopy.

Authors:  P H Silverstone; C C Hanstock; S Rotzinger
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

Review 2.  Current concepts in rapid cycling bipolar disorder.

Authors:  M D Shelton; J R Calabrese
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 3.  Rapid cycling bipolar disease: new concepts and treatments.

Authors:  S L Dubovsky
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 5.285

4.  Maternal choline status during pregnancy, but not that of betaine, is related to antenatal mental well-being: The growing up in Singapore toward healthy outcomes cohort.

Authors:  Linde van Lee; Phaik Ling Quah; Seang Mei Saw; Fabian K P Yap; Keith M Godfrey; Yap Seng Chong; Michael J Meaney; Helen Chen; Mary Foong-Fong Chong
Journal:  Depress Anxiety       Date:  2017-05-04       Impact factor: 6.505

Review 5.  Neurochemical predictors of response to pharmacologic treatments for bipolar disorder.

Authors:  Melissa P Delbello; Stephen M Strakowski
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 8.081

6.  Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate.

Authors:  Ren H Wu; Tina O'Donnell; Michele Ulrich; Sheila J Asghar; Christopher C Hanstock; Peter H Silverstone
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-07-30

7.  Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series.

Authors:  Michael I Gurevich; Cassandra L Robinson
Journal:  Glob Adv Health Med       Date:  2015-03

Review 8.  Mitochondrial Agents for Bipolar Disorder.

Authors:  Círia Pereira; Victor Chavarria; João Vian; Melanie Maree Ashton; Michael Berk; Wolfgang Marx; Olivia May Dean
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

9.  Mood disorders and complementary and alternative medicine: a literature review.

Authors:  Naseem Akhtar Qureshi; Abdullah Mohammed Al-Bedah
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-14       Impact factor: 2.570

10.  Altered neurochemistry in the anterior white matter of bipolar children and adolescents: a multivoxel 1H MRS study.

Authors:  Jonika Tannous; Bo Cao; Jeffrey A Stanley; Giovana B Zunta-Soares; Benson Mwangi; Marsal Sanches; Jair C Soares
Journal:  Mol Psychiatry       Date:  2020-11-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.